HAL MPE1
Alternative Names: HAL-MEP1; Peanut allergy immunotherapy - HAL Allergy; Peanut allergy vaccine - HAL Allergy; Peanut extract - HAL AllergyLatest Information Update: 28 Feb 2022
At a glance
- Originator HAL Allergy
- Class Allergens; Antiallergics; Food allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Peanut hypersensitivity
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for phase-I development in Peanut-hypersensitivity(In adolescents, In children, In adults) in Canada (SC)
- 28 Feb 2022 No recent reports of development identified for phase-I development in Peanut-hypersensitivity(In adolescents, In children, In adults) in USA (SC)
- 28 Feb 2020 HAL-MPE1 is still in phase I trials for Peanut hypersensitivity in USA (NCT02991885)